Cargando…
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759946/ https://www.ncbi.nlm.nih.gov/pubmed/31571677 http://dx.doi.org/10.2147/CEOR.S228414 |
Ejemplares similares
-
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019) -
Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
Publicado: (2017) -
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017) -
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
por: Olivares, José Manuel, et al.
Publicado: (2021) -
Real-life effectiveness of transitioning from paliperidone palmitate
1-monthly to paliperidone palmitate 3-monthly long-acting injectable
formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)